Switching from serotonin reuptake inhibitors to duloxetine in patients with resistant obsessive compulsive disorder: a case series

Abstract

Obsessive compulsive disorder (OCD) is a chronic disorder, currently recognized as one of the most common psychiatric disorder as well as one of the most disabling of all medical disorders. OCD is characterized by high rates of partial and/or absent response to standard, recommended treatments (serotonin reuptake inhibitors and psychotherapy). Recent investigation showed that Venlafaxine, a dual serotonin and norepinephrine reuptake inhibitor (SNRI), may be a valid alternative for some treatment-refractory patients. We present the cases of four OCD patients with comorbid mood or anxiety disorders, who were treated with serotonin reuptake inhibitors (SRIs) at adequate doses for at least 12 weeks, showing partial/no response. Patients were then switched to Duloxetine up to 120 mg/day and followed up for 12 weeks. Three out of four patients showed a Yale-Brown Obsessive Compulsive Scale

(Y-BOCS) score reduction ≥35%. Duloxetine may be helpful in patients with treatment-resistant OCD, although larger and controlled studies are warranted to confirm this preliminary observation.

Keywords

obsessive compulsive disorder (OCD)treatment-resistance serotonin and norepinephrine reuptake inhibitors (SNRIs)Duloxetine

Get full access to this article

View all access options for this article.

References

Bymaster F.P. , Dreshfield-Ahmad L.J. , Threlkeld P.G. et al. (2001) Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 25(6): 871—880

Dell'Osso B. , Nestadt G. , Allen A. , Hollander E. (2006) Serotonin-norepinephrine reuptake inhibitors in the treatment of obsessive-compulsive disorder: A critical review. J Clin Psychiatry 67(4): 600—610

Denys D. , van der Wee N. , van Megen H.J. , Westenberg H.G. (2003) A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder. J Clin Psychopharmacol 23(6): 568—575

de Mathis M.A. , Diniz J.B. , do Rosario M.C. et al. (2006) What is the optimal way to subdivide obsessive-compulsive disorder? CNS Spectr 11(10): 762—768, 771—774, 776—779

Engleman E.A. , Robertson D.W. , Thompson D.C. et al. (1996) Antagonism of serotonin 5-HT1A receptors potentiates the increases in extracellular monoamines induced by duloxetine in rat hypothalamus. J Neurochem 66: 599—603

First M.B. , Spitzer R.L. , Gibbon M. et al. (1997) Structured clinical interview for DSM-IV axis I (SCID-I) clinician version. American Psychiatric Press, Washington DC

Goodman W.K. , Price L.H. , Rasmussen S.A. et al. (1989) The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry 46(11): 1006—1011

Goodman W.K. , Price L.H. , Delgado P.L. et al. (1990) Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: comparison of fluvoxamine and desipramine. Arch Gen Psychiatry 47: 577—585

Greist J.H. , Bandelow B. , Hollander E. et al. (2003) WCA recommendations for the long-term treatment of obsessive-compulsive disorder in adults. CNS Spectr 8(8 Suppl 1): 7—16

10.

Hamilton M. (1959) The assessment of anxiety states by rating. Br J Med Psychol 32: 50—55

11.

Hamilton M. (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56—62

12.

Mallinckrodt C.H. , Raskin J. , Wohlreich M.M. et al. (2004) The efficacy of Duloxetine: a comprehensive summary of results from MMRM and LOCF_ANCOVA in eight clinical trials. BMC Psychiatry 4: 26

13.

Pallanti S. , Hollander E. , Bienstock C. et al. (2002) Treatment non-response in OCD: methodological issues and operational definitions. Int J Neuropsychopharmacol 5(2): 181—191

14.

Roseboom P.H. , Kalin N.H. (2000) Neuropharmacology of venlafaxine. Depress Anxiety 12(S1): 20—29

15.

Swindle R.W. , Mallinckrodt C. , Rosebaum J.F. et al. (2004) Efficacy of Duloxetine treatment: Analysis of pooled data from six placebo — and SSRI — controlled clinical trials. Eur Neuropsychopharmacol 14(S3): S190

16.

Thase M.E. , Lu Y. , Joliat M.J. et al. (2003) Remission in placebo-controlled trials of duloxetine with an SSRI comparator. Eur Neuropsychopharmacol 13(S4): S215

17.

Westanmo A.D. , Gayken J. , Haight R. (2005) Duloxetine. a balanced and selective norepinephrine- and serotonin-reuptake inhibitor. Am J Health-Syst Pharm 6: 2481—2490

18.

Wohlreich M.M. , Mallinckrodt C.H. , Prakash A. et al. (2007) Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation. Depress Anxiety 24(1): 41—52